CN104302327A - 放射氟化方法 - Google Patents

放射氟化方法 Download PDF

Info

Publication number
CN104302327A
CN104302327A CN201380015583.9A CN201380015583A CN104302327A CN 104302327 A CN104302327 A CN 104302327A CN 201380015583 A CN201380015583 A CN 201380015583A CN 104302327 A CN104302327 A CN 104302327A
Authority
CN
China
Prior art keywords
agent
tacn
formula
peptide
btm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015583.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.巴拉
S.K.卢思拉
G.赖德
W.莱瓦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
GE Healthcare Ltd
Original Assignee
University of Southampton
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton, GE Healthcare Ltd filed Critical University of Southampton
Priority to CN201811135640.8A priority Critical patent/CN109045312A/zh
Publication of CN104302327A publication Critical patent/CN104302327A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201380015583.9A 2012-01-23 2013-01-22 放射氟化方法 Pending CN104302327A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811135640.8A CN109045312A (zh) 2012-01-23 2013-01-22 放射氟化方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1201062.5 2012-01-23
GB201201062A GB201201062D0 (en) 2012-01-23 2012-01-23 Radiofluorination method
US201261589972P 2012-01-24 2012-01-24
US61/589972 2012-01-24
PCT/EP2013/051154 WO2013110615A1 (en) 2012-01-23 2013-01-22 Radiofluorination method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811135640.8A Division CN109045312A (zh) 2012-01-23 2013-01-22 放射氟化方法

Publications (1)

Publication Number Publication Date
CN104302327A true CN104302327A (zh) 2015-01-21

Family

ID=45840808

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380015583.9A Pending CN104302327A (zh) 2012-01-23 2013-01-22 放射氟化方法
CN201811135640.8A Pending CN109045312A (zh) 2012-01-23 2013-01-22 放射氟化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811135640.8A Pending CN109045312A (zh) 2012-01-23 2013-01-22 放射氟化方法

Country Status (8)

Country Link
US (1) US11135322B2 (https=)
EP (1) EP2806901B1 (https=)
JP (1) JP6609409B2 (https=)
KR (1) KR102046437B1 (https=)
CN (2) CN104302327A (https=)
AU (1) AU2013211639B2 (https=)
GB (1) GB201201062D0 (https=)
WO (1) WO2013110615A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201062D0 (en) 2012-01-23 2012-03-07 Ge Healthcare Ltd Radiofluorination method
GB201308053D0 (en) 2013-05-03 2013-06-12 Ge Healthcare Ltd Metal complexes and fluorination thereof
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
JP7062977B2 (ja) * 2018-01-30 2022-05-09 株式会社デンソーウェーブ 複数の無線機器をグルーピングする方法
CN113663621A (zh) * 2020-05-14 2021-11-19 益诺思生物技术海门有限公司 一种89Zr药物标记及纯化装置及其方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110110854A1 (en) * 2007-01-11 2011-05-12 Immunomedics, Inc. Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules
CN102123739A (zh) * 2007-12-19 2011-07-13 免疫医疗公司 用于蛋白质、肽和其他分子的改进的f-18标记方法和组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719041D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
WO2006138357A1 (en) 2005-06-14 2006-12-28 The University Of Akron Macrocyclic metal complexes for their use as anticancer agents
GB0524851D0 (en) * 2005-12-06 2006-01-11 Ge Healthcare Ltd Radiolabelling method using polymers
CN101568352B (zh) * 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
WO2009035959A2 (en) 2007-09-10 2009-03-19 Ge Healthcare Limited Radiofluorination methods
US8761016B2 (en) 2008-03-28 2014-06-24 Georgia Tech Research Corporation Systems and methods for intelligent policy enforcement in access networks
KR101106433B1 (ko) 2009-04-03 2012-01-18 서울대학교산학협력단 암 조직의 타겟팅을 위한 마크로사이클릭 아미노산 계열의 유도체 및 그의 방사성 또는 비방사성 금속 표지화합물
JP2013528180A (ja) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド 放射性標識化合物及びその製造方法
EP2651411B1 (en) * 2010-12-13 2020-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
CN102391168B (zh) 2011-09-16 2013-11-27 中山大学附属第一医院 对称性双功能偶联剂及其偶合分子显像剂
GB201201062D0 (en) 2012-01-23 2012-03-07 Ge Healthcare Ltd Radiofluorination method
GB201308053D0 (en) 2013-05-03 2013-06-12 Ge Healthcare Ltd Metal complexes and fluorination thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110110854A1 (en) * 2007-01-11 2011-05-12 Immunomedics, Inc. Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules
CN102123739A (zh) * 2007-12-19 2011-07-13 免疫医疗公司 用于蛋白质、肽和其他分子的改进的f-18标记方法和组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARA S. TREDGET ET AL.: "A Family of Scandium and Yttrium Tris((trimethylsilyl)methyl) Complexes with Neutral N3 Donor Ligands", 《ORGANOMETALLICS》 *
M. D. WARD: "The Coordination Chemistry of Macrocyclic Ligands", 《SCHOOL OF CHEMISTRY, CANTOCK"S CLOSE, BRISROL, BS8 1 TS》 *
SHARAD HAJELA ET AL.: "Highly electron deficient Group 3 organometallic complexes based on the 1,4,7-trimethyl-1,4,7-triazacyclononane ligand system", 《JOURNAL OF ORGANOMETALLIC》 *

Also Published As

Publication number Publication date
EP2806901A1 (en) 2014-12-03
KR20140114389A (ko) 2014-09-26
WO2013110615A1 (en) 2013-08-01
US11135322B2 (en) 2021-10-05
AU2013211639A1 (en) 2014-08-07
EP2806901B1 (en) 2016-03-30
US20140377178A1 (en) 2014-12-25
AU2013211639B2 (en) 2017-06-01
JP6609409B2 (ja) 2019-11-20
KR102046437B1 (ko) 2019-11-19
JP2015505533A (ja) 2015-02-23
CN109045312A (zh) 2018-12-21
GB201201062D0 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
CN103153350B (zh) 肽放射性示踪剂组合物
JP5860808B2 (ja) 放射性ヨウ素化方法
US20220031870A1 (en) Metal complexes and fluorination thereof
CN104302327A (zh) 放射氟化方法
JP6055417B2 (ja) 放射性トレーサー組成物
ES2929507T3 (es) Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT
KR20220034777A (ko) 화합물 및 사용 방법
CN105849067B (zh) 纯化方法和组合物
JP2016532700A (ja) 放射性標識方法
KR20130024963A (ko) 개선된 ｎ4 킬레이트제 결합체
JP2016520577A (ja) 金属錯体とそのフッ素化
CN104797273A (zh) 用于放射氟化的18f-标记的醛组合物
WO2014096191A1 (en) Bis 2h-imidazole-2-thione chelating agents as ligands for radiopharmaceutical in vivo imaging

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150121